Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC, UC-CM, and Triamcinolone Acetonide for Keloid Therapy
NCT05939817Phase 4Completed
- Sponsor
- Gatot Soebroto Central Army Hospital
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised trial of human umbilical cord mesenchymal stem cells and human umbilical cord mesenchymal stem cell secretome in keloid (3 arms), sponsored by Gatot Soebroto Central Army Hospital. Primary endpoints: Type 1:3 collagen ratio reduction at 17 weeks and Interleukin-10 levels increase at 17 weeks. Started Oct 2021; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cellshuman umbilical cord mesenchymal stem cell secretome
03
Conditions
keloid
Beyond the preview
Go deeper on NCT05939817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939817.